값Q4, 24Q4, 25TTM판매비·일반관리비———연구개발———영업 이익———비영업 수익, 합계———이자비용(자본화한 이자 차감 후)———이자비용을 제외한 비영업 수익———비정상 수입/지출———세전소득———지분법 손익———세금———비지배 지분———세후 기타 수익/비용———중단된 사업 부문 제외 순이익———중단된 사업———순이익———희석보정———우선배당———보통주주에게 귀속되는 희석 순이익———주당 순이익(기본 EPS)———희석 주당 순이익 (희석 EPS)———평균 발행주식수———희석주식수———EBITDA———EBIT———매출원가———기타 매출원가———감가상각 및 무형자산 상각 (현금흐름)———
Novartis AG
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz.